First AD

Second AD

PPAR Agonists for Treatment of PBC

Video content above is prompted by the following:

We now have FDA-approved PPAR agonists for the management of PBC in combination with UDCA or as monotherapy for patients who are intolerant to UDCA. What is the scientific basis for use of PPAR agonists in PBC? And how are these different than fibrates?

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Peer Exchange

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Video Series

Expanding Treatment Options for Primary Biliary Cholangitis with Novel Therapies

PPAR agonists have emerged as a therapeutic option for primary biliary cholangitis (PBC), either in combination with ursodeoxycholic acid (UDCA) or as monotherapy for those intolerant to UDCA. These agents work by modulating lipid metabolism, inflammation, and fibrosis through activation of peroxisome proliferator-activated receptors. Unlike fibrates, which primarily target PPAR-alpha, newer PPAR agonists may have broader receptor activity, potentially offering enhanced efficacy. The approval of these agents by the FDA underscores their clinical relevance and provides an alternative for patients with PBC who have limited treatment options.

The panel of experts explore the use of FDA-approved peroxisome proliferator-activated receptor (PPAR) agonists in the management of primary biliary cholangitis (PBC), discussing their scientific basis, how they differ from fibrates, and their role in combination with ursodeoxycholic acid (UDCA) or as monotherapy for UDCA-intolerant patients.